Recent News for TILS - Tiziana Life Sciences Pl

Date Title
May 7 Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
May 5 Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.
Apr 30 Stocks That Soared on Covid Treatments Are Coming Back to Earth
Apr 27 Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT
Apr 14 TLSA: Accustem Converging on NASDAQ
Apr 13 Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.
Apr 12 TLSA: In a Tizzy About Tiziana
Mar 30 Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program
Mar 30 Tiziana Life Sciences plc: Accustem Update
Mar 30 TLSA: Foralumab Gains Expanded Access for SPMS and Advances to Phase II in COVID
Mar 30 Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Mar 29 Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021
Mar 29 Tiziana Life Sciences plc ("Tiziana" or the "Company") - Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today
Mar 17 Bitcoin Marks Huge Milestone In Mainstream Acceptance
Feb 26 Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
Feb 18 ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
Feb 16 Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
Feb 5 Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
Feb 3 Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
Feb 3 Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
Feb 2 Tiziana Life Sciences' Shares Rally As Foralumab Shows Encouraging Action In COVID-19 Study In Brazil
Feb 2 TLSA: COVID-19 Brazilian Study Topline Data Released
Feb 2 Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
Jan 27 Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission
Jan 20 Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT
Back to the Main TILS Page...